top of page
AEnB2Uq_HIiXrr6Uye1O7aZ5edPEz3r8ICmVEm8k9WIpa8GnDYiuQwMuSahKqwy82Yi7yRhU9ZSJdY5rzHIdRqOnNl

NET EDUCATIONAL EVENT
Focus on Pheochromocytoma/Paraganglioma

Wednesday, Jan 11, 2023

Join LACNETS for a unique webinar with a live presentation of three pheochromocytoma and paraganglioma (PPGL) cases and an engaging panel discussion with experts Dr. Jaydira Del Rivero, Dr. Erik Mittra, and Dr. Karel Pacak.

Registration is closed.

ABOUT THE SPEAKERS

jaydi_delrivero.jpg

JAYDIRA DEL RIVERO, MD

Endocrinologist, Oncologist, National Cancer Institute 

Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. 

Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors.

She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies.  Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology.

Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma.

Mittra, Erik_large.jpg

ERIK MITTRA, M.D., PhD

Radiologist, Nuclear Medicine, OHSU

Dr. Erik Mittra received his medical and graduate training through the MSTP (joint MD/PhD) program at Stony Brook University in New York in 2005. He subsequently completed a Nuclear Medicine residency and fellowship at Stanford University. He was faculty in Radiology at Stanford for 8 years, until moving to OHSU in 2018.

Dr. Mittra is interested in all aspects of Nuclear Medicine imaging, therapy, and research. Targeted Radioisotope Therapies (TRT) are of particular interest; including various applications in oncology and he is a nationally-recognized expert in this area. His research interests are primarily focused on the clinical translation of novel radioisotopes for imaging and therapy. He is very involved with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the North American Neuroendocrine Tumor Society (NANETS), and is the current Medical Director of the Healing NET Foundation (HNF).

052013-pacak.jpg

KAREL PACAK, M.D., PhD, DSc

Endocrinologist, NIH

Dr. Karel Pacak graduated summa cum laude from Charles University, Prague, Czech Republic in 1984. In 1990 he began his postdoctoral fellowship at NINDS under Drs. Kopin and Goldstein. Then in 1995 Dr. Pacak began his residency in internal medicine at the Washington Hospital Center under Dr. L. Wartofsky, followed by a fellowship in endocrinology, diabetes, and metabolism at NIH. He was Board certified in 1998 and 1999 in those disciplines.

In 1998 he established a new Program for Neuroendocrine Tumors focusing on pheochromocytoma and paraganglioma at NICHD. He received his Ph.D. in1993 and his D.Sc. in 1998 in the field of neuroendocrinology from Charles University. In 2006 he was awarded a lifetime professorship in Internal Medicine at Charles University. 

 

Dr. Pacak is an internationally recognized expert in the diagnosis and treatment of neuroendocrine tumors, especially pheochromocytoma and paraganglioma. Dr. Pacak also established the International Symposia on Pheochromocytoma. He also helped co-found a new Asian Alliance for the Study of Neuroendocrine Tumors in 2010. He is a recipient of numerous awards including the Peter Heimann Memorial Award at Yale University, International Association of Endocrine Surgeons; NIH Director's Mentoring Award, Award for Cure from Pheo & Para Alliance, NICHD Director's Award of Merit, Pincus Taft Memorial Lecture the Highest Award from Endocrine Society of Australia, Jessenius Gold Medal from Slovak Academy of Sciences, Outstanding Clinical Endocrinologist from the American Association of Clinical Endocrinologists and recently Outstanding Clinical Investigator (to be given in 2022) from the US Endocrine Society as well as Team Science Award from American Association for Cancer Research. Dr. Pacak is the author of more than 520 scientific peer-reviewed articles, 140 book chapters, and 6 books.

RESOURCES

THANKS TO OUR SPONSORS

AAA+Logo.png
Ipsen_Logo (1).png
itm-logo-claim-rgb-high-res.png
Lantheus_Logo_TM_RGB.png
bottom of page